Claudia Maggioni

Monza, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

The evolution of a luminal breast cancer to a triple-negative and its impact on disease control with sacituzumab govitecan.

The evolution of a luminal breast cancer to a triple-negative and its impact on disease control with sacituzumab govitecan.

Journal: Recenti progressi in medicina
Published: October 24, 2024

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.

Journal: BMC cancer
Published: April 29, 2022

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story.

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story.

Journal: Life (Basel, Switzerland)
Published: January 18, 2022

A new factor involved during childbirth labor: the importance of having a good dental occlusion.

A new factor involved during childbirth labor: the importance of having a good dental occlusion.

Journal: Journal of biological regulators and homeostatic agents
Published: July 22, 2021

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.

Journal: BMC cancer
Published: September 08, 2020

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

Journal: Journal of clinical medicine
Published: September 16, 2019

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: July 11, 2019

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.

Journal: Journal of translational medicine
Published: September 28, 2018

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.

Journal: International journal of molecular sciences
Published: April 07, 2017

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.

Journal: British journal of cancer
Published: May 26, 2016

Advances in treatment of mesothelioma.

Advances in treatment of mesothelioma.

Journal: Expert opinion on pharmacotherapy
Published: April 08, 2016

Belagenpumatucel-L for the treatment of non-small cell lung cancer.

Belagenpumatucel-L for the treatment of non-small cell lung cancer.

Journal: Expert opinion on biological therapy
Published: July 28, 2015
Showing 1-12 of 14

Last Updated: 09/26/2026